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Abstract
At the request of French Regulatory Authorities, a new formulation of  Levothyrox® was licensed in France in 2017, with the 
objective of avoiding the stability deficiencies of an existing licensed formulation. Before launching the new formulation, an 
average bioequivalence (ABE) trial was conducted, having enrolled 204 subjects and selected for interpretation a narrow a 
priori bioequivalence range of 0.90–1.11. Bioequivalence was concluded. In a previous publication, we questioned the ability 
of an ABE trial to guarantee the switchability within patients of the new and old levothyroxine formulations. It was suggested 
that the two formulations should be compared using the conceptual framework of individual bioequivalence. The present paper 
is a response to those claiming that, despite the fact that ABE analysis does not formally address the switchability of the two 
formulations, future patients will nevertheless be fully protected. The basis for this claim is that the ABE study was estab‑
lished in a large trial and analyzed using a stringent a priori acceptance interval of equivalence. These claims are questionable, 
because the use of a very large number of subjects nullifies the implicit precautionary intention of the European guideline when, 
for a Narrow Therapeutic Index drug, it recommends shortening the a priori acceptance interval from 0.80–1.25 to 0.90–1.11.
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Key Points 
The use of a large number of subjects for an average bio‑
equivalence (ABE) trial for Narrow Therapeutic Index 
drugs should be questioned.
Regarding the size of the within‑subject variability, use 
of a large number of subjects for an ABE trial nullifies a 
precautionary intention implicit in the European Union 
bioequivalence guideline when it recommends shorten‑
ing the a priori acceptance interval.
For Narrow Therapeutic Index drugs, if an ABE data 
analysis trial is planned, it is proposed that, as a minimal 
requirement, a fully replicated design be required to 
compare test and reference products using the within‑
subject variability.
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1 Introduction
In France, almost 3 million patients are currently receiving 
levothyroxine, a Narrow Therapeutic Index (NTI) drug and, 
prior to 2017, most were prescribed  Levothyrox®, a tablet 
formulation marketed by Merck Serono. In March 2017, at 
the request of French Authorities, a new formulation (NF) 
of  Levothyrox®  (Levothyrox®NF) was licensed in France 
to replace the old formulation (OF), for which stability 
deficiencies had been demonstrated. The single active drug 
(known as synthetic L‑thyroxine, levothyroxine, or L‑T4) 
was the same in both formulations; only the excipients were 
changed, with the replacement of lactose by mannitol and 
citric acid.  Levothyrox®NF is marketed in France, Swit‑
zerland, and Turkey; it was launched in Germany in April 
2019 and it is anticipated that the NF will receive marketing 
approval in 21 European Union (EU) member states [1].
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Whilst both formulations have been shown to be bio‑
equivalent based on EU‑recommended bioequivalence 
guidelines [2], adverse drug reactions were reported in sev‑
eral thousand patients using the NF [3, 4]. The number of 
reports, for a simple formulation substitution of the prod‑
uct with, quantitatively, the same active ingredient, was 
unprecedented. In June 2019, the French Agency released 
a pharmaco‑epidemiological survey comparing 1,037,553 
patients treated in 2016 with the OF versus 1,037,553 sub‑
jects treated in 2017 with the NF and it was concluded that 
approximately 20% of patients had ceased using the NF at 
the end of 2017 compared with 3% for the paired group 
treated with the OF in 2016 [5]. These figures are compara‑
ble to the rate of switchback, defined as the switching from a 
branded drug to a generic and then back to the branded drug 
reported for some antiepileptic drugs with an NTI. Examples 
are valproic acid and some other antiepileptic drugs versus 
antihyperlipidemics and antidepressants [6].
In attempting to document the altered health status of 
the NF in some patients, we published a report [7] in which 
we questioned the ability of a classical bioequivalence trial, 
based on EU guidelines, to ensure the switchability between 
the two formulations of levothyroxine. Because introduction 
of the NF resulted in a major public crisis, the raw data of 
the bioequivalent dossier were placed in the public domain. 
From these data, we computed that almost 70% of the 204 
healthy volunteers enrolled into this successful (from a 
regulatory perspective) average bioequivalence (ABE) trial 
were outside the a priori bioequivalence range selected of 
0.90–1.11. We concluded that this very high number of sub‑
jects placed a question mark over switchability of the formu‑
lations. Indeed, in accordance with the original articles on 
this topic by Anderson and Hauck in 1990 [8] and 1994 [9], a 
clear distinction should be made between prescribability (the 
possibility of using the reference product or the generic at 
initiation of the treatment) and switchability (the possibility 
of switching one formulation with another in a given patient 
already under treatment). The current rule for ABE guar‑
antees prescribability but not switchability. This is because 
only an individual bioequivalence (IBE) assessment formally 
aims to compare the exposure obtained with each formulation 
within each individual subject, thereby ensuring that each 
individual will be similarly exposed to the two formulations.
2  Why the Use of a Large Number 
of Subjects for an Average Bioequivalence 
(ABE) Trial should be Questioned
Following our earlier publication [7], some opinion leaders 
have claimed that the ABE for  Levothyrox® was robustly 
established because (1) it was demonstrated with a very 
large number of subjects (n = 204); and (2) the classical 
bioequivalence acceptance interval was shortened from 
0.80–1.25 to 0.90–1.11. Implicitly, the message conveyed 
was that any future patients will be appropriately protected, 
because bioequivalence was established in a large trial and 
the analysis was based on a stringent a priori bioequivalent 
acceptance interval.
In this article, we explain why these two lines of argu‑
ment based on ABE are flawed, and we argue for the polar 
opposite opinion. Indeed, in an ABE analysis, a small a 
priori bioequivalence acceptance interval provides no sup‑
plementary protection to a future patient against the risk 
of an individual bio‑unequivalence when, additionally, the 
demonstration of this required ABE had succeeded using 
an atypically very large number of subjects. It is essential 
to appreciate just what an ABE can and cannot guarantee 
and what, moreover, is the precise meaning and regulatory 
expectation when recommending a more stringent 0.90–1.11 
bioequivalence interval.
By ABE definition, two products are deemed bioequiv‑
alent if the 90% confidence intervals of geometric mean 
test/reference exposure (μT/μR) ratios for maximum con‑
centration (Cmax) and area under the concentration–time 
curve (AUC) fall within the a priori bioequivalence limits 
of 80–125% (usual case) or 90–110% (exceptional case), 
following the EU guideline, which states: “In specific cases 
of products with a narrow therapeutic index, the acceptance 
interval for AUC should be tightened to 90.00–111.11%” 
[10]. This simply means that (1) an ABE can only guar‑
antee that the μT/μR ratio of the median bioavailability is 
located, with a 5% statistical protection, within a regulatory 
pre‑defined bioequivalence interval; and (2) that reducing 
this a priori bioequivalence from 0.8–1.25 to 0.90–1.11 
merely requires, for a given number of patients, a smaller 
residual reflecting variability of both formulations that is 
implicitly desirable for a NTI drug. It should be understood 
that an ABE formally considers the subjects enrolled in a 
trial as ‘experimental material’ (they can be regarded as 
running chromatograph columns) which a priori shares 
exactly the same ratio of geometric mean μT/μR between 
the two formulations. Therefore, any individual departure 
from this value may be classified as ‘experimental noise’ 
and not as variability having any biological relevance. The 
consequence is that requiring a narrower interval to accept 
a bioequivalence range simply guarantees a low level of 
experimental noise and, in turn, increases confidence in 
the conclusion that the two formulations are, on average, 
bioequivalent.
To summarize, an ABE trial does not provide any guar‑
antee on the individual status of each subject enrolled in the 
trial, regardless of the width of the a priori bioequivalence 
acceptance interval. All ABE ensures is protection against 
the risk of a large departure from unity of the μT/μR ratio 
in in vivo conditions.
Why So Many Subjects to Demonstrate the Bioequivalence of  Levothyrox®?
A widely held view, which may be described as a ‘lax’ 
interpretation of what ABE actually establishes, amongst 
both healthcare professionals and regulatory authorities is 
that switchability is established between two formulations as 
a ‘by‑product’ of an ABE trial. For example, in a retrospec‑
tive analysis conducted by US Food and Drug administration 
(FDA) scientists, comparing generic and innovator product 
bioequivalence data from 2070 clinical bioequivalence 
studies, it was stated “The statistical approach used by the 
FDA to analyze BE study data is designed to minimize the 
risk in situations where the patient is switched to a generic 
version of a medication that he or she is currently taking” 
and “The robust performance of bioequivalence testing in 
generic drug approvals over many years lends strong support 
to the FDA’s belief that health professionals can substitute 
drug products determined to be therapeutically equivalent 
with the full expectation that the generic product will pro‑
duce the same clinical effect and safety profile as the innova‑
tor product” (emphasis added) [10]. For the reasons outlined 
in the following sections, we do not concur with this opin‑
ion, for those drugs having a NTI, even when the a priori 
bioequivalence interval is tightened to 0.9–1.11
3  A Large Number of Subjects for an ABE 
Trial Nullifies the Precautionary 
Intention of the European Union (EU) 
Bioequivalence Guideline when it 
Recommends Shortening t11he A Priori 
Acceptance Interval from 0.80–1.25 
to 0.90–1.11
Most ABE studies are typically conducted with 24–36 sub‑
jects [11] enrolled into a 2 × 2 crossover design, whereas 
for the  Levothyrox® study the number of subjects was 204. 
As for clinical trials, bioequivalence trial protocols must 
be submitted to and approved by an ethical committee, 
with a justification for the planned number of subjects 
(actually 216 for this trial) [2]. From the selection of this 
very large sample size, it seems likely that the company 
knew or surmised that a large number of subjects would 
be required to demonstrate bioequivalence based on ABE. 
Axiomatically, it follows that a much smaller number of 
subjects (e.g., typically 24–36) would have led to rejec‑
tion of a bioequivalence conclusion on the basis of ABE. 
We explored this hypothesis using bootstrapping. After 
sampling 10,000 subsamples from the available raw data 
(i.e., 204 subjects taking the two formulations—as we had 
no access to the actual crossover design), we estimated 
the likelihood to conclude bioequivalence with a classi‑
cal sample size (n = 24 subjects) to be only 10.2%. With 
bootstrap samples of 48 and 98 subjects, the likelihood to 
conclude bioequivalence increased to 42.3% and 87.8%, 
and it is with 150 subjects that the ABE would definitely 
be demonstrated (99.8%). When such a large number of 
subjects is required to demonstrate bioequivalence, it is 
appropriate to, first, identify the factors determining the 
large number and, second, reflect on the consequences of 
interpreting the results of the ABE.
It should be recognized that, when the average μT/
μR ratio is equal or close to 1:1, as presently is the case 
for  Levothyrox® (estimated average ratio of 0.993:1) [2], 
it is always possible to demonstrate an ABE merely by 
increasing the number of subjects. This is so, even when 
the NF has a very poor reproducibility in its performance, 
i.e., a large within‑ (intra‑) subject variability (WSV). The 
WSV is generally expressed as the coefficient of varia‑
tion (CV%) of the analysis of variance (ANOVA) residual 
and it is a matter of major importance from the patient 
perspective, especially when treated with an NTI drug, 
because it reflects the day‑to‑day variability of exposure 
to the formulation. Drugs for which this residual term is 
greater than 30% are classified as highly variable drugs 
[12]. According to the FDA, “it is believed that highly 
variable drugs generally have a wide therapeutic window; 
in other words, despite high variability, these products 
have been demonstrated to be both safe and effective” 
[11]. Axiomatically, it can be concluded that a product 
formulation of a highly variable drug is highly undesir‑
able for any drug with an NTI and this is supported by 
FDA scientists, for whom one of the characteristics of 
an NTI drug is that it has a low‑to‑moderate WSV [13]. 
We note that, in an overview on the WSV of NTI drugs, 
it was reported by the FDA that the mean WSV for levo‑
thyroxine was only 9.3%, with a range of 3.8–15.5%, for 
the AUC in nine bioequivalence trials [13]. For the old 
and new  Levothyrox® products, the very large number of 
planned subjects to demonstrate an ABE was likely attrib‑
utable to an anticipated high WSV, rather than to devia‑
tion of μT/μR from unity, as confirmed by the actually 
measured value of 23.7% [2]. Hence, to propose tighten‑
ing the a priori bioequivalence confidence intervals, in 
order to protect future patients, is unsound, as there is a 
trade‑off between the number of subjects required to dem‑
onstrate an ABE and the width of the selected bioequiva‑
lence interval. This is because the width of the confidence 
interval is directly proportional to the intra‑subject CV% 
and inversely proportional to the square root of the num‑
ber of subjects. In other words, increasing the number of 
subjects in an ABE contradicts the implicit spirit of the 
international regulation, when it is used to tighten the 
bioequivalence interval for NTI drugs with a μT/μR ratio 
equal or close to 1:1.
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4  For Narrow Therapeutic Index Drugs, 
it is Important to Place in Perspective 
the Number of Subjects in an ABE Trial 
and to Conduct a Bioequivalence Trial 
Measuring Intra‑Subject Variability
In order to resolve these issues for the old and new 
 Levothyrox® formulations, a new replicated bioequiva‑
lence trial, based on ad hoc analysis could be conducted. 
A first option would be to tentatively analyze the trial 
according to IBE rather than ABE concepts, as recently 
undertaken for gabapentin [14]. Like levothyroxine, 
gabapentin is a critical drug in terms of bioequivalence. 
Alternatively, as proposed by FDA, the same replicated 
trial could be analyzed following a reference‑scaled ABE 
approach, as suggested for NTI drugs, i.e., scaling the 
bioequivalence limits of a test product to the WSV of 
the reference product to compare the mean as well as the 
WSV. This has been explored and discussed recently by 
others [15] and is proposed in draft FDA guidance spe‑
cifically devoted to levothyroxine. Once finalized, this 
guidance will represent the FDA’s thinking on this topic 
[16].
5  Conclusion
In the future, it would be wise to explore the risk of declar‑
ing a highly variable drug with an NTI as bioequivalent 
simply by enrolling a large total number of subjects in an 
ABE trial, in order to mitigate an unduly large WSV. More 
broadly, there is a need to establish scientifically sound 
bioequivalence standards for NTI drugs in Europe. Finally, 
it should be reiterated that, even if the ABE approach and 
the two‑way crossover constitute the general rule in the 
EU, in particular circumstances a company should not be 
disallowed from exploring alternative replicated designs 
and data analysis, such as population bioequivalence to 
document prescribability and IBE to support switchability 
between formulations.
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